171 related articles for article (PubMed ID: 11851626)
1. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy.
Miyoshi Y; Uemura H; Kitami K; Satomi Y; Kubota Y; Hosaka M
BJU Int; 2001 Dec; 88(9):982-3. PubMed ID: 11851626
[No Abstract] [Full Text] [Related]
2. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
3. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
Moul JW; Zlotta AR
BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
[No Abstract] [Full Text] [Related]
5. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
6. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
7. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment for biochemical relapse after radiotherapy.
Quero L; Hennequin C
Cancer Radiother; 2014 Oct; 18(5-6):540-4. PubMed ID: 25179255
[TBL] [Abstract][Full Text] [Related]
9. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
10. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
12. [Small cell carcinoma of the prostate: a case report].
Sakai H; Tsuruta T; Wajiki M
Hinyokika Kiyo; 2004 Apr; 50(4):269-71. PubMed ID: 15188622
[TBL] [Abstract][Full Text] [Related]
13. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
14. The clinical and biological study of androgen independent prostate cancer (AI PCa).
Logothetis CJ; Hoosein NM; Hsieh JT
Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155
[No Abstract] [Full Text] [Related]
15. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
[TBL] [Abstract][Full Text] [Related]
16. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
Grossfeld GD; Small EJ; Lubeck DP; Latini D; Broering JM; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):56-64. PubMed ID: 11502450
[TBL] [Abstract][Full Text] [Related]
19. Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.
Lipianskaya J; Cohen A; Chen CJ; Hsia E; Squires J; Li Z; Zhang Y; Li W; Chen X; Xu H; Huang J
Asian J Androl; 2014; 16(4):541-4. PubMed ID: 24589459
[TBL] [Abstract][Full Text] [Related]
20. Androgen suppression strategies for prostate cancer: is there an ideal approach?
Ismail M; Ferroni M; Gomella LG
Curr Urol Rep; 2011 Jun; 12(3):188-96. PubMed ID: 21384154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
